GNCA Key Statistics, Chart & Performance
The current stock price of GNCA is 0.051 null. In the past month the price decreased by -80.31%. In the past year, price decreased by -97.8%.
GNCA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.34 | 406.46B | ||
| AMGN | AMGEN INC | 15.22 | 179.22B | ||
| GILD | GILEAD SCIENCES INC | 15.35 | 155.97B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.68 | 117.51B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.49 | 82.76B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 782.35 | 52.71B | ||
| INSM | INSMED INC | N/A | 37.69B | ||
| NTRA | NATERA INC | N/A | 32.37B | ||
| BIIB | BIOGEN INC | 10.56 | 25.94B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.46 | 22.12B | ||
| INCY | INCYTE CORP | 15.7 | 19.78B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.27B |
Related stock screener links
About GNCA
Company Profile
Genocea Biosciences, Inc. engages in the development and commercialization of cancer vaccines. The company is headquartered in Cambridge, Massachusetts and currently employs 74 full-time employees. The company went IPO on 2014-02-05. The firm is focused on discovering and developing cancer immunotherapies using its Antigen Lead Acquisition System (ATLAS) platform. The ATLAS platform can profile each patient's CD4+ and CD8+ T cell immune responses to every potential target or antigen identified by sequencing of that patient's tumor. Its product candidates include GEN-011 and GEN-009. GEN-011 is an investigational solid tumor cell therapy candidate, which consists of CD4+ and CD8+ neoantigen-targeted peripheral T cells (NPTs) which are specific for up to 30 antigens, designed to limit tumor escape. GEN-011 consists of T cells extracted from the patient’s peripheral blood and specific for ATLAS-prioritized neoantigens. GEN-009 is a neoantigen vaccine candidate delivering adjuvanted synthetic long peptides spanning ATLAS-identified anti-tumor neoantigens. The firm is evaluating its Phase I/IIa of GEN-009.
Company Info
GENOCEA BIOSCIENCES INC
100 Acorn Park Dr
Cambridge MASSACHUSETTS 02140 US
CEO: William Clark
Employees: 74
Phone: 16178768191.0
GENOCEA BIOSCIENCES INC / GNCA FAQ
What does GNCA do?
Genocea Biosciences, Inc. engages in the development and commercialization of cancer vaccines. The company is headquartered in Cambridge, Massachusetts and currently employs 74 full-time employees. The company went IPO on 2014-02-05. The firm is focused on discovering and developing cancer immunotherapies using its Antigen Lead Acquisition System (ATLAS) platform. The ATLAS platform can profile each patient's CD4+ and CD8+ T cell immune responses to every potential target or antigen identified by sequencing of that patient's tumor. Its product candidates include GEN-011 and GEN-009. GEN-011 is an investigational solid tumor cell therapy candidate, which consists of CD4+ and CD8+ neoantigen-targeted peripheral T cells (NPTs) which are specific for up to 30 antigens, designed to limit tumor escape. GEN-011 consists of T cells extracted from the patient’s peripheral blood and specific for ATLAS-prioritized neoantigens. GEN-009 is a neoantigen vaccine candidate delivering adjuvanted synthetic long peptides spanning ATLAS-identified anti-tumor neoantigens. The firm is evaluating its Phase I/IIa of GEN-009.
Can you provide the latest stock price for GENOCEA BIOSCIENCES INC?
The current stock price of GNCA is 0.051 null. The price decreased by -15% in the last trading session.
Does GENOCEA BIOSCIENCES INC pay dividends?
GNCA does not pay a dividend.
How is the ChartMill rating for GENOCEA BIOSCIENCES INC?
GNCA has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is the analyst forecast for GNCA stock?
9 analysts have analysed GNCA and the average price target is 3.14 null. This implies a price increase of 6060% is expected in the next year compared to the current price of 0.051.
Can you provide the PE ratio for GNCA stock?
GENOCEA BIOSCIENCES INC (GNCA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.52).
Should I buy GNCA stock?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on GNCA.
GNCA Technical Analysis
GNCA Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to GNCA. GNCA has a bad profitability rating. Also its financial health evaluation is rather negative.
GNCA Financial Highlights
Over the last trailing twelve months GNCA reported a non-GAAP Earnings per Share(EPS) of -0.52. The EPS increased by 40.23% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | -1947.12% | ||
| ROA | -95.88% | ||
| ROE | N/A | ||
| Debt/Equity | 0.24 |
GNCA Forecast & Estimates
9 analysts have analysed GNCA and the average price target is 3.14 null. This implies a price increase of 6060% is expected in the next year compared to the current price of 0.051.
For the next year, analysts expect an EPS growth of -58.43% and a revenue growth -46.87% for GNCA